The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAccess Intelligence Regulatory News (ACC)

Share Price Information for Access Intelligence (ACC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 60.50
Bid: 60.00
Ask: 61.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 60.50
ACC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pulsar update

6 Feb 2020 07:00

RNS Number : 1294C
Access Intelligence PLC
06 February 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

 

6th February 2020

ACCESS INTELLIGENCE PLC

Completion of Pulsar Accounting Review

Further to the announcement on 10 December 2019, the Board of Access Intelligence provides the following update following the completion of the review by an external firm of accountants of the accounts of the Pulsar business at closing.

In October 2019, Access Intelligence acquired the Pulsar business (comprising both Fenix Media Limited, which is incorporated in the UK, and Face US, which is incorporated in the US) from Cello Health plc ("Cello"). Following the identification of certain accounting questions on some contracts within Pulsar post acquisition, the Board of Access Intelligence commissioned an accounting review to be undertaken by independent accountants BDO.

Following completion of the BDO review, an adjustment of the previously disclosed unaudited financial results for Pulsar is required. Post this adjustment, for the year to 31 December 2018 Pulsar reported unaudited revenues of £6.8 million, gross profit of £3.8 million and an Adjusted EBITDA loss of £0.7 million. Upon acquisition by Access Intelligence, Pulsar's accounting reference period was amended. For the 11 month period to 30 November 2019, Pulsar would have had reported unaudited revenue of £5.2 million, gross profit of £2.3 million and an Adjusted EBITDA loss of £1.7 million.

Pursuant to the terms of the sale and purchase agreement signed on 2 October 2019 (the "Agreement"), and under the completion accounts reconciliation process agreed by both sides, Cello Health has agreed to pay Access Intelligence a net cash sum of £1.6m reflecting the shortfall in net assets delivered at closing versus the agreed target closing position.

In full and final settlement of any dispute under the Agreement regarding the appropriate valuation of the business, Cello Health has agreed that 4,076,238 of the consideration shares will be sold back to Access Intelligence for £1. As Access Intelligence currently does not have the requisite approvals to acquire these shares, a shareholder's meeting will be convened to obtain the necessary approval for the buy back. Upon completion of the buy back the relevant shares will be cancelled.

The post-acquisition contribution of Pulsar to Access Intelligence's consolidated financial results for the year to 30 November 2019 is expected to be revenue of £0.7 million, gross profit of £0.2 million and an Adjusted EBITDA loss of £0.5 million, prior to any acquisition accounting adjustments. The annual accounts may also be impacted by a potential non-cash write down. This is currently being discussed with the accountants and an update will be provided in due course.

This outcome of the financial analysis has no impact on the rationale for the Pulsar acquisition which is in line with a strategic ambition to strengthen capabilities in social media analysis, audience segmentation and social media marketing evaluation. Recurring revenues with Pulsar are around 70% of total revenue.

Related Party Transaction

Cello is a related party of the Company for the purposes of the AIM Rules by virtue of their status as substantial shareholders holding 10% or more or more of the Company's existing ordinary share capital.

The Board consider, having consulted with the Company's nominated adviser, finnCap, that the settlement with Cello set out above is fair and reasonable insofar as the Company's shareholders are concerned.

Commenting on the resolution of this matter, Joanna Arnold, CEO, said:

"Due to Cello Health's proactive engagement, we are pleased to have reached a swift and satisfactory resolution. The rationale for the acquisition remains unchanged and we look forward to growing the business as part of the Access Intelligence portfolio."

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

 

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance - Marc Milmo / Kate Bannatyne / Matthew Radley / Kate Washington

Corporate Broking - Alice Lane / Sunila de Silva

 

About Access Intelligence

 Access Intelligence PLC is a tech innovator, delivering high quality SaaS products that address the fundamental business needs of more than 3,500 global brands in the PR, communications and marketing industries. Listed on AIM, Access Intelligence provides technology that helps organisations understand what's important to their customers and their brand as they navigate a constantly changing world of politics, news and social media. This is alongside the practical tools and information to ensure their communications are relentlessly effective in building awareness, reputation and engagement.

 The expanding portfolio includes Vuelio, the platform that helps organisations make their stories matter; ResponseSource, a network that connects media and influencers to the resources they need, fast; and Pulsar, an audience insights and social listening platform.

 

- ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSIEEIESSESE
Date   Source Headline
19th Apr 20244:57 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSProposed Change of Name
25th Mar 20247:00 amRNSAccelerating ARR growth for Q1 2024
16th Jan 20247:00 amRNSTrading Update
18th Oct 20237:00 amRNSSignificant customer contract wins in ANZ
4th Jul 20237:00 amRNSInterim Results
22nd Jun 20237:00 amRNSTrading Update
23rd May 20232:30 pmRNSResult of Annual General Meeting
10th May 20235:45 pmRNSHolding(s) in Company
21st Apr 20233:00 pmRNSPosting of notice of AGM
17th Apr 20237:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 NOVEMBER 2022
13th Mar 20237:00 amRNSSilicon Valley Bank
3rd Mar 20237:00 amRNSBoard Changes
10th Feb 20237:00 amRNSContract wins
8th Feb 20233:45 pmRNSHolding(s) in Company
30th Jan 202312:25 pmRNSHolding(s) in Company
21st Dec 20221:43 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSTrading Update
28th Jul 20223:45 pmRNSExercise of Options, Treasury Shares & TVR
5th Jul 20227:00 amRNSInterim Results
1st Jul 20227:00 amRNSTotal Voting Rights
17th Jun 20227:00 amRNSTrading Update
14th Jun 20229:40 amRNSHolding(s) in Company
25th May 20223:15 pmRNSResult of Annual General Meeting
29th Apr 20225:00 pmRNSPosting of Notice of AGM
25th Apr 20227:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 NOVEMBER 2021
7th Apr 20227:00 amRNSContract Wins
6th Apr 20222:52 pmRNSHolding(s) in Company
6th Apr 202212:30 pmRNSHolding(s) in Company
25th Feb 202212:15 pmRNSDirector/PDMR Shareholding
4th Feb 20226:01 pmRNSHolding(s) in Company
18th Jan 202212:45 pmRNSDirector/PDMR Shareholding
17th Jan 20224:05 pmRNSDirector/PDMR Shareholding
17th Jan 20227:00 amRNSTrading Update
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 20218:00 amRNSHolding(s) in Company
9th Nov 20214:10 pmRNSExercise of Warrants and Total Voting Rights
18th Oct 20218:15 amRNSCopyright Tribunal Ruling
4th Oct 20217:00 amRNSBoard Changes
4th Oct 20217:00 amRNSEstablishment of Long-Term Value Creation Plan
7th Sep 20216:01 pmRNSHolding(s) in Company
7th Sep 202110:50 amRNSHolding(s) in Company
3rd Sep 20215:51 pmRNSHolding(s) in Company
3rd Sep 20215:50 pmRNSHolding(s) in Company
2nd Sep 20218:15 amRNSCompletion of Acquisition and Re-Admission
1st Sep 20218:00 amRNSSuccessful Implementation of Scheme of Arrangement
27th Aug 20219:05 amRNSHolding(s) in Company
27th Aug 20217:00 amRNSHolding(s) in Company
25th Aug 202112:20 pmRNSPosting of Supplementary AIM Admission Document
20th Aug 20217:00 amRNSScheme Effective, Director Shareholdings & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.